Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707135 · ClinicalTrials.gov registry record · Phase 1
Rapamycin in Advanced Cancers
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00707135 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 40 participants.
The verdict
NCT00707135, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.
Interventions
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00707135
The ClinicalTrials.gov registry entry for NCT00707135 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapamycin is the first listed.
NCT00707135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00707135 about?
NCT00707135 is a clinical study titled "Rapamycin in Advanced Cancers". The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.
What is the current status of trial NCT00707135?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-06. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00707135?
The interventions under investigation include: Rapamycin (DRUG).
Who is sponsoring clinical trial NCT00707135?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.